Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml
Z Gastroenterol 2020; 58(07): 672-692
DOI: 10.1055/a-1193-5475
DOI: 10.1055/a-1193-5475
Leitlinie
Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie – offene Fragen und Antworten
Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers
Zusammenfassung
Die COVID-19-Pandemie ist ein weltweiter Ausbruch von neu aufgetretenen Infektionen mit dem SARS-CoV-2-Virus, von denen weltweit derzeit mehr als 10.670.000 Menschen erkrankt sind bzw. waren. In Deutschland leiden ca. 450.000 Patienten an einer chronisch entzündlichen Darmerkrankung; diese Patienten benötigen in der Regel eine kontinuierliche und kompetente Betreuung. Vor dem Hintergrund eines rasch zunehmenden Wissenszuwachses haben 68 Experten, die die derzeit gültigen Leitlinien der DGVS zum Morbus Crohn und zur Colitis ulcerosa erstellt haben, im Rahmen einer virtuellen Konferenz aktuelle und praxisnahe Empfehlungen formuliert, um die Versorgung von CED-Patienten zu verbessern. Diese adressieren das Infektionsrisiko einschließlich des Risikos für besondere Gruppen, den möglichen Verlauf der Erkrankung und die Konsequenzen für die medikamentöse und die operative Therapie der Grunderkrankung sowie allgemeine Maßnahmen zur Infektionsprävention und adjuvante Präventions- und Therapiemöglichkeiten.
Publication History
Article published online:
13 July 2020
© Georg Thieme Verlag KG
Stuttgart · New York
-
Literatur
- 1 Ghebreyesus TA. WHO Director-General's opening remarks at the media briefing on COVID-19–11 March 2020. In. 2020 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
- 2 Burisch J, Kiudelis G, Kupcinskas L. et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2018;
- 3 Burisch J, Katsanos KH, Christodoulou DK. et al Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. J Crohns Colitis 2019; 13: 198-208 . doi:10.1093/ecco-jcc/jjy154
- 4 Kucharzik T, Dignass AU, Atreya R. et al. Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). Z Gastroenterol 2019; 57: 162-241
- 5 Evidence OCfE-bMLo. 2020 http://www.cebm.net/index.aspx?o=1025 , letzter Aufruf: 26.04.2020.
- 6 Novel Coronavirus Pneumonia Emergency Response Epidemiology T. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 145-151 . doi:10.3760/cma.j.issn.0254-6450.2020.02.003
- 7 Deng SQ, Peng HJ. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med 2020; 9
- 8 RKI. 2020 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.html letzter Aufruf am 16.05.2020.
- 9 WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). In. 2020 https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
- 10 Jin X, Lian JS, Hu JH. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;
- 11 Rodriguez-Lago I, Ramirez de la Piscina P, Elorza A. et al. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology 2020;
- 12 IOIBD. 2020 https://covidibd.org/ ; letzter Aufruf am 12.05.2020
- 13 Carvalho A, Alqusairi R, Adams A. et al. SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis: Implications for Detection and Transmission of COVID-19 Disease. The American journal of gastroenterology 2020;
- 14 Chen L, Lou J, Bai Y. et al COVID-19 Disease With Positive Fecal and Negative Pharyngeal and Sputum Viral Tests. The American journal of gastroenterology 2020; 115: 790 . doi:10.14309/ajg.0000000000000610
- 15 Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 2020; 158: 1518-1519 . doi:10.1053/j.gastro.2020.02.054
- 16 Chen N, Zhou M, Dong X. et al Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513 . doi:10.1016/S0140-6736(20)30211-7
- 17 Guan WJ, Ni ZY, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;
- 18 Wu J, Liu J, Zhao X. et al. Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis 2020;
- 19 Dreher M, Kersten A, Bickenbach J. et al Charakteristik von 50 hospitalisierten COVID-19-Patienten mit und ohne ARDS. Dtsch Arztebl Int 2020; 117: 271-278 . doi:10.3238/arztebl.2020.0271
- 20 ECDC. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK- ninth update. 2020
- 21 RKI. 2020 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html letzter Aufruf am 15.05.2020
- 22 Grunert PC, Reuken PA, Stallhofer J. et al. IBD in the COVID-19 pandemic – the patients’ perspective. 2020
- 23 Mao R, Liang J, Shen J. et al Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol 2020; 5: 426-428 . doi:10.1016/S2468-1253(20)30076-5
- 24 Norsa L, Indriolo A, Sansotta N. et al. Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology 2020;
- 25 Taxonera C, Sagastagoitia I, Alba C. et al. 2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases. Alimentary pharmacology & therapeutics 2020;
- 26 Allocca M, Fiorino G, Zallot C. et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2020;
- 27 Lavezzo E, Franchin E, Ciavarella C. et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. medRxiv 2020;
- 28 Gudbjartsson DF, Helgason A, Jonsson H. et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med 2020;
- 29 Armann JPDN, Simon A, Doenhardt M. et al Hospital admission in children and adolescents with COVID-19 — early results from a national survey conducted by the German Society for Pediatric Infectious Diseases (DGPI). Dtsch Arztebl Int 2020; 117: 373-374 . doi:10.3238/arztebl.2020.0373
- 30 Turner D, Huang Y, Martin-de-Carpi J. et al. COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr 2020;
- 31 Tinsley A, Navabi S, Williams ED. et al. Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2018;
- 32 Ko MK, Ng SC, Mak LY. et al Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis. Journal of digestive diseases 2016; 17: 610-617 . doi:10.1111/1751-2980.12397
- 33 Magro FRJ-F, Abeu C, McMahon E. et al Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do’s and don’ts from the ECCO-COVID Taskforce. J Crohns Colitis 2020
- 34 Pin An MJ, Haixia R, Juan S. et al Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan, China. The Lancet 2020; ePub ahead of print
- 35 Bin Abdulrahman AK, Bin Abdulrahman KA, Almadi MK. et al Do various personal hygiene habits protect us against influenza-like illness?. BMC Public Health 2019; 19: 1324 . doi:10.1186/s12889-019-7726-9
- 36 Cheng HY, Jian SW, Liu DP. et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. JAMA internal medicine 2020;
- 37 Wölfel R, Corman VM, Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;
- 38 Ng K, Poon BH, Kiat Puar TH. et al. COVID-19 and the Risk to Health Care Workers: A Case Report. Ann Intern Med 2020;
- 39 Zabana Y, Rodriguez L, Lobaton T. et al Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality. Journal of Crohn’s & colitis 2019; 13: 828-837 . doi:10.1093/ecco-jcc/jjz013
- 40 Damiani G, Pacifico A, Bragazzi NL. et al Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther 2020; e13475 . doi:10.1111/dth.13475
- 41 Long MD, Martin C, Sandler RS. et al Increased risk of pneumonia among patients with inflammatory bowel disease. The American journal of gastroenterology 2013; 108: 240-248 . doi:10.1038/ajg.2012.406
- 42 Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Therapeutic advances in chronic disease 2013; 4: 167-185 . doi:10.1177/2040622313485275
- 43 Dorrington AM, Selinger CP, Parkes GC. et al. The historical role and contemporary use of corticosteroids in inflammatory bowel disease. J Crohns Colitis 2020;
- 44 Lichtenstein GR, Feagan BG, Cohen RD. et al Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. The American journal of gastroenterology 2012; 107: 1409-1422 . doi:10.1038/ajg.2012.218
- 45 Wisniewski AKJ, Seksik P, Landman C. et al. the Saint-Antoine IBD network, Collaborators Saint Antoine IBD Network. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurine. United European Gastroenterology Journal 2020; 8 (03) 303-313
- 46 Seksik P, Cosnes J, Sokol H. et al Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Alimentary pharmacology & therapeutics 2009; 29: 1106-1113 . doi:10.1111/j.1365-2036.2009.03973.x
- 47 Kirchgesner J, Lemaitre M, Carrat F. et al Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology 2018; 155: 337-346.e310 . doi:10.1053/j.gastro.2018.04.012
- 48 Kochar B, Cai W, Cagan A. et al. Pre-treatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients with Inflammatory Bowel Diseases. Gastroenterology 2020;
- 49 Fleming SB. Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines (Basel) 2016; 4
- 50 Kelesidis T, Mastoris I, Metsini A. et al How to approach and treat viral infections in ICU patients. BMC Infect Dis 2014; 14: 321 . doi:10.1186/1471-2334-14-321
- 51 Favalli EG, Biggioggero M, Maioli G. et al. Baricitinib for COVID-19: a suitable treatment?. The Lancet Infectious diseases 2020;
- 52 Feagan BG, Bhayat F, Khalid M. et al Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. J Crohns Colitis 2018; 12: 905-919 . doi:10.1093/ecco-jcc/jjy047
- 53 Zabotti A, Goletti D, Lubrano E. et al The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 2020; 19: 69-82 . doi:10.1080/14740338.2020.1703946
- 54 Rubin DT, Abreu MT, Rai V. et al. Management of Patients with Crohn’s Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology 2020;
- 55 Linton NM, Kobayashi T, Yang Y. et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med 2020; 9
- 56 Toruner M, Loftus Jr EV, Harmsen WS. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936
- 57 Tosca J, Garcia N, Pascual I. et al Clinical assessment of risk factors for infection in inflammatory bowel disease patients. Int J Colorectal Dis 2020; 35: 491-500 . doi:10.1007/s00384-019-03501-0
- 58 Bezzio C, Saibeni S, Variola A. et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020;
- 59 (ISS) ISdS. Sorveglianza Integrata COVID-19 in Italia 2020. 2020 https://wwwepicentroissit/coronavirus/bollettino/Infografica_26marzo%20ITApdf)
- 60 RKI. Täglicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). 27.04–AKTUALISIERTER STAND FÜR DEUTSCHLAND. 2020 https://wwwrkide/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-27-depdf?__blob=publicationFile
- 61 Statista. 2020 https://de.statista.com/statistik/daten/studie/1365/umfrage/bevoelkerung-deutschlands-nach-altersgruppen/ letzter Aufruf am 01.05.2020
- 62 Destatis. 2020 https://www.destatis.de/DE/Presse/Pressemitteilungen/2020/03/PD20_115_132.html;jsessionid=7F326250BEDCBE087ABE219A28DE59F5.internet8712 ; letzter Aufruf am 01.05.2020
- 63 Soziales BfAu. 2020 https://www.bmas.de/DE/Presse/Pressemitteilungen/2020/einheitlicher-arbeitsschutz-gegen-coronavirus.html ; letzter Aufruf am 01.05.2020
- 64 Colombel JF, D’Haens G, Lee WJ. et al Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2020; 14: 254-266 . doi:10.1093/ecco-jcc/jjz131
- 65 Strohl M, Gonczi L, Kurt Z. et al Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?. World journal of gastroenterology 2018; 24: 2363-2372 . doi:10.3748/wjg.v24.i22.2363
- 66 Huang C, Wang Y, Li X. et al Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506 . doi:10.1016/S0140-6736(20)30183-5
- 67 Occhipinti V, Pastorelli L. Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy. Inflamm Bowel Dis 2020;
- 68 de Jong MJ, Boonen A, van der Meulen-de Jong AE. et al. Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. Clin Gastroenterol Hepatol 2020;
- 69 de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ. et al Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet 2017; 390: 959-968 . doi:10.1016/S0140-6736(17)31327-2
- 70 RKI. 2020 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/nCoV.html ; letzter Aufruf am 08.05.2020
- 71 RKI. 2020 https://www.kvn.de/Information+zum+Coronavirus+%28SARS_CoV2+COVID+19%29-p-6072.html ; letzter Aufruf am 01.05.2020
- 72 Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis 2017; 23: 894-902 . doi:10.1097/MIB.0000000000001082
- 73 Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 74-80 . doi:10.3109/00365521.2014.987809
- 74 Haisma SM, Galaurchi A, Almahwzi S. et al Head-to-head comparison of three stool calprotectin tests for home use. PLoS One 2019; 14: e0214751 . doi:10.1371/journal.pone.0214751
- 75 Kucharzik T, Wittig BM, Helwig U. et al Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2017; 15: 535-542 e532 . doi:10.1016/j.cgh.2016.10.040
- 76 Maaser C, Petersen F, Helwig U. et al. Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. Gut 2019;
- 77 Repici A, Pace F, Gabbiadini R. et al. Endoscopy units and the COVID-19 Outbreak: A Multi-Center Experience from Italy. Gastroenterology 2020;
- 78 Repici A, Maselli R, Colombo M. et al. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know. Gastrointest Endosc 2020;
- 79 Johnston ER, Habib-Bein N, Dueker JM. et al Risk of bacterial exposure to the endoscopist’s face during endoscopy. Gastrointest Endosc 2019; 89: 818-824 . doi:10.1016/j.gie.2018.10.034
- 80 van Doremalen N, Bushmaker T, Morris DH. et al Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564-1567 . doi:10.1056/NEJMc2004973
- 81 Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 2020;
- 82 Xiao F, Tang M, Zheng X. et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 2020;
- 83 Song Y, Liu P, Shi XL. et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut 2020;
- 84 Hamming I, Timens W, Bulthuis ML. et al Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-637 . doi:10.1002/path.1570
- 85 Prevention. CfDCa. Coronavirus Disease 2019 (COVID-19). Available at (letzter Aufruf am 15.05.2020): 2020 https://www.cdc.gov/coronavirus/2019-ncov/infection-control/infection-prevention-control-faq.html
- 86 Control. ECfDPa. Infection prevention and control for COVID-19 in healthcare settings. Available at (letzter Aufruf am 15.05.2020): 2020 https://www.ecdc.europa.eu/en/publications-data/infection-prevention-and-control-covid-19-healthcare-settings
- 87 Gralnek IM, Hassan C, Beilenhoff U. et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. Endoscopy 2020;
- 88 Sultan S, Lim JK, Altayar O. et al. AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology 2020;
- 89 Chiu PWY, Ng SC, Inoue H. et al. Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements). Gut 2020;
- 90 Han J, Wang Y, Zhu L. et al. Preventing the spread of COVID-19 in digestive endoscopy during the resuming period: meticulous execution of screening procedures. Gastrointest Endosc 2020;
- 91 Iacucci M, Cannatelli R, Labarile N. et al. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol 2020;
- 92 Neumann H, Emura F, Bokemeyer B. et al. Practical Advice for Management of IBD Patients during the COVID-19 Pandemic: A World Endoscopy Organization Statement. Dig Endosc 2020;
- 93 Vavricka SR, Tutuian R, Imhof A. et al Air suctioning during colon biopsy forceps removal reduces bacterial air contamination in the endoscopy suite. Endoscopy 2010; 42: 736-741 . doi:10.1055/s-0030-1255615
- 94 Neurath MF. Covid-19 and immunomodulation in IBD. Gut 2020;
- 95 Euroimmun. 2020 https://www.coronavirus-diagnostik.de ; letzter Aufruf am 01.05.2020
- 96 Euroimmun. https://www.coronavirus-diagnostik.de/documents/Indications/Infections/Coronavirus/YI_2606_I_DE_B.pdf. 2020 letzter Aufruf am 01.05.2020
- 97 Streeck Hea. Vorläufiges Ergebnis und Schlussfolgerungen der COVID-19 Case Cluster Study (Gemeinde Gangelt) in land. nrw 942020 2020; S4
- 98 Taskforce. PDCAobotC-E. 2020 https://ecco-ibd.eu/images/6_Publication/6_8_Surveys/1st_interview_COVID-19%20ECCOTaskforce_published.pdf ; letzter Aufruf am 29.03.2020
- 99 Papamichael K, Karatzas P, Mantzaris GJ. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn’s Disease. J Crohns Colitis 2016; 10: 371-372 . doi:10.1093/ecco-jcc/jjv206
- 100 Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency clinicians. Emergency medicine practice 2020; 22: 1-28
- 101 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395: 473-475 . doi:10.1016/s0140-6736(20)30317-2
- 102 Wu C, Chen X, Cai Y. et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine 2020;
- 103 Ling Y, Xu SB, Lin YX. et al Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chinese medical journal 2020; 133: 1039-1043 . doi:10.1097/cm9.0000000000000774
- 104 Liang-Ru Zhu RM, Gionata Fiorino, Thomas Schneider on behalf of the COVID-19 ECCO Taskforce. 2020 https://ecco-ibd.eu/images/6_Publication/6_8_Surveys/2nd_Interview_COVID-19_ECCO_Taskforce_published.pdf ; letzter Aufruf am 29.03.2020
- 105 Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 2020;
- 106 Winthrop KL, Melmed GY, Vermeire S. et al Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis 2018; 24: 2258-2265 . doi:10.1093/ibd/izy131
- 107 Boor PPC, de Ruiter PE, Asmawidjaja PS. et al JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa. Transl Res 2017; 188: 67-79 . doi:10.1016/j.trsl.2016.11.006
- 108 Jamilloux Y, Henry T, Belot A. et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmunity reviews 2020;
- 109 Stebbing J, Phelan A, Griffin I. et al COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious diseases 2020; 20: 400-402 . doi:10.1016/s1473-3099(20)30132-8
- 110 Spinelli FR, Conti F, Gadina M. HiJAKing SARS-CoV-2?. The potential role of JAK inhibitors in the management of COVID-19. Science immunology 2020; 5. doi: 10.1126/sciimmunol.abc5367
- 111 Torres J, Bonovas S, Doherty G. et al ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis 2020; 14: 4-22 . doi:10.1093/ecco-jcc/jjz180
- 112 Roblin X, Boschetti G, Williet N. et al Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Alimentary pharmacology & therapeutics 2017; 46: 142-149 . doi:10.1111/apt.14106
- 113 Boyapati RK, Torres J, Palmela C. et al Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn’s disease. The Cochrane database of systematic reviews 2018; 5: Cd012540 . doi:10.1002/14651858.CD012540.pub2
- 114 Van Assche G, Magdelaine-Beuzelin C, D’Haens G. et al Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868 . doi:10.1053/j.gastro.2008.03.004
- 115 Chen L, Liu HG, Liu W. et al [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43: 203-208 . doi:10.3760/cma.j.issn.1001-0939.2020.03.013
- 116 Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine 2018; 101: 14-18 . doi:10.1016/j.cyto.2016.08.003
- 117 Ng SC, Hilmi IN, Blake A. et al Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflamm Bowel Dis 2018; 24: 2431-2441 . doi:10.1093/ibd/izy153
- 118 Van Assche G, Vermeire S, Noman M. et al Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. J Crohns Colitis 2010; 4: 329-333 . doi:10.1016/j.crohns.2009.12.012
- 119 Fukuyo S, Saito K, Yamaoka K. et al Efficacy and safety of reducing duration of infliximab infusion. Modern rheumatology 2014; 24: 275-280 . doi:10.3109/14397595.2013.843747
- 120 El-Matary W, Dykes DMH, Bauman L. et al Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience. Inflamm Bowel Dis 2017; 23: 2104-2108 . doi:10.1097/mib.0000000000001259
- 121 Sandborn WJ, Baert F, Danese S. et al Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020; 158: 562-572.e512 . doi:10.1053/j.gastro.2019.08.027
- 122 Ruemmele FM, Veres G, Kolho KL. et al Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014; 8: 1179-1207 . doi:10.1016/j.crohns.2014.04.005
- 123 Stevens T, Haasnoot LDHG, Buskens C. et al. Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s disease: Long-term follow-up of the LIR!C trial. Journal of Crohn’s and Colitis 2020; 14: S003-S004
- 124 Ponsioen CY, de Groof EJ, Eshuis EJ. et al Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. The lancet Gastroenterology & hepatology 2017; 2: 785-792 . doi:10.1016/S2468-1253(17)30248-0
- 125 RKI. Epidemiologisches Bulletin 18 | 2020 30. April 2020. letzter Aufruf am 01.05.2020 2020
- 126 Sachar DB. Placebo-controlled clinical trials in gastroenterology. A position paper of the American College of Gastroenterology. The American journal of gastroenterology 1984; 79: 913-917
- 127 Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-663 . doi:10.1016/s0140-6736(09)61963-2
- 128 Preiß JC, Bokemeyer B, Buhr HJ. et al [Updated German clinical practice guideline on “Diagnosis and treatment of Crohn’s disease” 2014]. Z Gastroenterol 2014; 52: 1431-1484 . doi:10.1055/s-0034-1385199
- 129 Nguyen GC, Bernstein CN, Bitton A. et al Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146: 835-848.e836 . doi:10.1053/j.gastro.2014.01.042
- 130 Terpos E, Ntanasis-Stathopoulos I, Elalamy I. et al. Hematological findings and complications of COVID-19. American journal of hematology 2020;
- 131 Llitjos JF, Leclerc M, Chochois C. et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Journal of thrombosis and haemostasis: JTH 2020;
- 132 Kollias A, Kyriakoulis KG, Dimakakos E. et al. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. British journal of haematology 2020;
- 133 Balestrieri P, Ribolsi M, Guarino MPL. et al. Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients 2020; 12
- 134 Massironi S, Rossi RE, Cavalcoli FA. et al Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clinical nutrition (Edinburgh, Scotland) 2013; 32: 904-910 . doi:10.1016/j.clnu.2013.03.020
- 135 Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008; 14: 1105-1111 . doi:10.1002/ibd.20429
- 136 Schreiner P, Martinho-Grueber M, Studerus D. et al. Nutrition in Inflammatory Bowel Disease. Digestion 2020;
- 137 Beck MA, Handy J, Levander OA. Host nutritional status: the neglected virulence factor. Trends in microbiology 2004; 12: 417-423 . doi:10.1016/j.tim.2004.07.007
- 138 Calder PC, Carr AC, Gombart AF. et al. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients 2020; 12
- 139 Gasmi A, Noor S, Tippairote T. et al. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clinical immunology (Orlando, Fla) 2020;